Adrian Rawcliffe, president of GlaxoSmithKline’s venture capital business unit, is taking over as GSK’s senior vice president for worldwide business development, research and development.

Rawcliffe takes over from Moncef Slaoui, who is chairman of research and development. Rawcliffe will now be responsible for all in-licensing, collaborations and alliance management. His previous position was managing partner and president of SR One Ltd., GSK’s venture arm.

GSK operates one of its two U.S. headquarters in Research Triangle Park.